APOA-V: Heparin-Like Protein Involved in Lipoprotein Metabolism

Target Name: APOA5

NCBI ID: G116519

APOA5

APOA-V: Heparin-Like Protein Involved in Lipoprotein Metabolism

APOA-V (ApoA-V) is a protein that is expressed in the liver and is involved in the metabolism of apolipoprotein A-V (APOA-V). It is a heparin-like protein that has four unique domains: a variable region, a constant region, a variable region, and a C-terminus.

The variable region of APOA-V is made up of 25% of the protein and is responsible for the recognition of different lipoprotein particles. The constant region is made up of 20% of the protein and is responsible for the stability of the protein. The variable region and the constant region are both involved in the recognition of different lipoprotein particles, but the variable region is responsible for the recognition of very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL).

The C-terminus of APOA-V is made up of 15% of the protein and is responsible for the stability of the protein. It is also involved in the recognition of different lipoprotein particles, but it is not as important as the variable region in this process.

APOA-V is a protein that is expressed in the liver and is involved in the metabolism of APOA-V. It is a heparin-like protein that has four unique domains: a variable region, a constant region, a variable region, and a C-terminus. The variable region is responsible for the recognition of different lipoprotein particles, the constant region is responsible for the stability of the protein, and the C-terminus is responsible for the stability of the protein.

In conclusion, APOA-V is a protein that is expressed in the liver and is involved in the metabolism of APOA-V. It is a heparin-like protein that has four unique domains: a variable region, a constant region, a variable region, and a C-terminus. The variable region is responsible for the recognition of different lipoprotein particles, the constant region is responsible for the stability of the protein, and the C-terminus is responsible for the stability of the protein. Further research is needed to understand the role of APOA-V in the metabolism of APOA-V and to determine if it can be a drug target or biomarker.

Protein Name: Apolipoprotein A5

Functions: Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and an inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate) (By similarity). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages. Binds heparin (PubMed:17326667)

The "APOA5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about APOA5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets